



## PANCREASURE, IMMUNOVIA'S NEXT-GENERATION TEST FOR EARLY DETECTION OF PANCREATIC CANCER

Immunovia (publ) today announced PancreaSure as the brand name for its next-generation blood-based test for early detection of pancreatic cancer, a key milestone ahead of the planned U.S. commercial launch in Q3 2025.

"The name PancreaSure embodies the benefit of our test: providing accurate pancreatic cancer detection to give medical professionals and patients clarity and reassurance when they need it most," said Jeff Borcharding, CEO of Immunovia.

PancreaSure has demonstrated strong clinical performance across multiple studies, achieving 78% sensitivity and 92% specificity in identifying early-stage pancreatic cancer. This performance meets or exceeds that of the most common screening methods used today. In contrast to current common methods, which are more invasive and burdensome for patients, PancreaSure is a simple blood test.

"Compared to our prior test, PancreaSure represents a very different test run on a different testing platform. That warranted a new name to mark significant advancement for pancreatic cancer screening for high-risk individuals. With PancreaSure, we want to transform early detection when survival chances are dramatically higher," Borcharding said.

PancreaSure is set to launch commercially in the United States in the third quarter of 2025, initially targeting approximately 200 specialized centers that run high-risk pancreatic cancer surveillance programs.

**For further information, please contact**

Jeff Borcharding, CEO

[jeff.borcharding@immunovia.com](mailto:jeff.borcharding@immunovia.com)

**Immunovia in brief**

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.

USA is the world's largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm.

For more information, please visit [www.immunovia.com](http://www.immunovia.com).